Bahl Center Will Transform Approach to Precision Cancer Medicine
Two gifts totaling $13.75 million establish a one-of-a-kind metabolomics and imaging research program at Stony Brook
Understanding the metabolism of cancer at its most complicated cellular levels is an essential approach to advance cancer research and patient outcomes. Add new imaging tools and technology that can map tumors with more precision than ever before and you have a new, one-of-a-kind translational research resource, soon to be located at the Stony Brook University Cancer Center.
Made possible by two back-to-back gifts from Kavita and Lalit Bahl totaling $13.75 million, the new Kavita and Lalit Bahl Center for Metabolomics and Imaging advances the family’s vision to elevate Stony Brook Medicine to the cutting-edge of personalized cancer research, diagnostic imaging breakthroughs and evolving individualized cancer care far beyond where it currently exists. Metabolomics is an emerging field in cancer investigation with the most promising approach to individualized cancer treatment because uncovering metabolic pathways is a key to unlocking their influence on the development and proliferation of cancer cells.
Under the guidance of Yusuf Hannun, MD, and Lina Obeid, MD, the Bahl Center brings together Stony Brook researchers in the fields of metabolomics, cancer biology, medical imaging, and computational oncology. Dr. Hannun, Director of the Stony Brook Cancer Center, is a renowned physician-scientist whose career has spanned more than 30 years as a cancer clinician and researcher investigating the lipid mediators of cancer cell signaling. He has published more than 500 scientific papers, edited seven books and holds seven patents. Dr. Obeid, Vice Dean for Research at Stony Brook University School of Medicine, manages approximately $75 million in research grants and is a nationally renowned researcher in cancer biology who has been continuously funded by the National Institutes of Health for over 20 years.
For the full article, click here.